| Assessment Status | Rapid Review Complete |
| HTA ID | 25001 |
| Drug | Maralixibat |
| Brand | Livmarli® |
| Indication | Maralixibat (Livmarli®) is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. |
| Assessment Process | |
| Rapid review commissioned | 06/01/2025 |
| Rapid review completed | 04/02/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of maralixibat compared with the current standard of care. |
